Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Budget setbacks happen, but recovery is possible. Learn a practical plan to diagnose errors, restore discipline, and regain financial momentum.
11,251 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Investors confront a Musk-power dilemma: bet on SpaceX's growth trajectory or Tesla's robotics push. This analysis br...
AST SpaceMobile faced a sharp weekly drop after announcing a large convertible debt raise. This article explains why ...
If you’re building a portfolio meant to last, choosing the right coffee stock matters. This guide compares Dutch Bros...
Hyperliquid's native token continues a sharp weekly decline, reviving bearish bets as traders weigh on-chain signals ...
Are the best-known stocks truly a massive opportunity or a trap built by hype? This guide breaks down 10 popular name...
The Bank of Japan unveils a sandbox to test whether central bank reserves can run on blockchain rails, a landmark ste...
Vitalik Buterin unveils Sanctuary Tech, hinting at a new endgame for Ethereum. The idea arrives as macro volatility w...
Artificial intelligence is reshaping medicine, from drug discovery to patient care. This article spotlights two healt...
Ethereum rose above 2,000 while a scarcity signal on Binance turned positive, suggesting thinner sell-side liquidity....
Ethereum surged to a six-week high as institutional buying and treasury activity boosted ETH. This article breaks dow...
As volatility rises and headlines loom, investors ask: is the S&P 500 headed correction? This guide breaks down what ...